Smith & Nephew (LON:SN) had its price target hoisted by Credit Suisse Group from GBX 1,285 ($18.02) to GBX 1,290 ($18.09) in a research note issued to investors on Friday. The firm presently has a “neutral” rating on the stock. Credit Suisse Group’s target price points to a potential upside of 5.13% from the company’s previous close.

A number of other analysts also recently weighed in on the stock. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 1,411 ($19.78) price target on shares of Smith & Nephew in a report on Wednesday. Berenberg Bank reissued a “hold” rating and issued a GBX 1,340 ($18.79) price target on shares of Smith & Nephew in a report on Friday, November 3rd. Jefferies Group reissued a “buy” rating and issued a GBX 1,515 ($21.24) price target on shares of Smith & Nephew in a report on Monday, November 6th. Deutsche Bank increased their price target on shares of Smith & Nephew from GBX 1,200 ($16.83) to GBX 1,315 ($18.44) and gave the company a “hold” rating in a report on Monday, October 23rd. Finally, Citigroup reissued a “sell” rating and issued a GBX 1,160 ($16.26) price target on shares of Smith & Nephew in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. Smith & Nephew currently has a consensus rating of “Hold” and an average target price of GBX 1,322.50 ($18.54).

Shares of Smith & Nephew (LON:SN) opened at GBX 1,227 ($17.20) on Friday. Smith & Nephew has a 1-year low of GBX 1,143 ($16.03) and a 1-year high of GBX 1,442 ($20.22). The firm has a market cap of $10,720.00 and a price-to-earnings ratio of 1,947.62.

In other Smith & Nephew news, insider Angie Risley acquired 1,601 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was bought at an average price of GBX 1,249 ($17.51) per share, for a total transaction of £19,996.49 ($28,037.70).

WARNING: This piece was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.